Bifogade filer
PDF
Beskrivning
| Land | Frankrike |
|---|
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2026-02-16 09:13:53
Sartorius Stedim Biotech SA / Key word(s): Annual Results Aubagne, France | February 16, 2026 Sartorius Stedim Biotech releases Universal Registration Document 2025 Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2025 including the Annual Financial Report. The document is available at the following link: https://www.sartorius.com/urd2025 Financial calendar March 24, 2026 | Annual Shareholders' Meeting April 23, 2026 | Publication of the first quarter results for January to March 2026 July 23, 2026 | Publication of half-year results for January to June 2026 October 22, 2026 | Publication of nine-month results January to September 2026 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3 billion euros, according to preliminary figures. Currently, more than 10,200 employees are working for customers around the globe. Visit our newsroom and follow us on LinkedIn. Contact Verena Sattel External Communications +49 551 308 9261 verena.sattel@sartorius.com Attachment File: Sartorius Stedim Biotech releases Universal Registration Document 2025 | Media Release Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | sartorius.presse@sartorius.com |
| Internet: | www.sartorius.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2275078 |
| End of Announcement - EQS News Service | |
2275078 16-Feb-2026 CET/CEST